GROSSO ® Reshaper FIH Trial: New Clinical Site Approved in Italy

The GROSSO ® Reshaper First-In-Human (FIH) trial is expanding its reach in Italy following the approval from the "Comitato Etico Territoriale Lazio Area 3" and the formal authorization from the Italian Ministry of Health.

This regulatory milestone enables the initiation of a new clinical site at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome. Under the expert guidance of Principal Investigator Dr. Romina Fasciani and Collaborating Investigator Prof. Luigi Mosca, the opening of this site is set to significantly accelerate patient enrollment and the overall progress of the study.